drugset / Trial / NCT03592706
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Phase 2/3
Unknown
60 enrolled
Ivy Life Sciences, Co., Ltd
Tri-Service General Hospital (TSGH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in： 1. Reduction of tumor size 2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.
Timeline
- Start
- 2009-12
- Primary completion
- 2021-02
- Completion
- 2021-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Immune Killer Cells | Unknown | — | — |